<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38333218</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1664-3224</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in immunology</Title><ISOAbbreviation>Front Immunol</ISOAbbreviation></Journal><ArticleTitle>Case report: Ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases.</ArticleTitle><Pagination><StartPage>1287300</StartPage><MedlinePgn>1287300</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1287300</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2024.1287300</ELocationID><Abstract><AbstractText>Persistent COVID-19 is a well recognized issue of concern in patients with hematological malignancies. Such patients are not only at risk of mortality due to the infection itself, but are also at risk of suboptimal malignancy-related outcomes because of delays and terminations of chemotherapy. We report two lymphoma patients with heavily pretreated persistent COVID-19 in which ensitrelvir brought about radical changes in the clinical course leading to rapid remissions. Patient 1 was on ibrutinib treatment for mantle cell lymphoma when he developed COVID-19 pneumonia which was severe and ongoing for 2 months despite therapy with molnupiravir, multiple courses of remdesivir, one course of sotrovimab, tocilizumab, and steroids. Patient 2 was administered R-CHOP therapy for diffuse large B-cell lymphoma when he developed COVID-19 which was ongoing for a month despite treatment with multiple courses of remdesivir and one course of sotrovimab. A 5-day administration of ensitrelvir promptly resolved the persistent COVID-19 accommodated by negative conversions of RT-qPCR tests in both patients within days. Ensitrelvir is a novel COVID-19 therapeutic that accelerates viral clearance through inhibition of the main protease of SARS-CoV-2, 3-chymotrypsin-like protease, which is vital for viral replication. Ensitrelvir is a promising treatment approach for immunocompromised lymphoma patients suffering from persisting and severe COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Furuya, Yasuda, Hiki, Shirane, Yamana, Uchimura, Inano, Takaku, Hamano and Ando.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Furuya</LastName><ForeName>Chiho</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yasuda</LastName><ForeName>Hajime</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hiki</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirane</LastName><ForeName>Shuichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamana</LastName><ForeName>Tomohito</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uchimura</LastName><ForeName>Ayana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inano</LastName><ForeName>Tadaaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takaku</LastName><ForeName>Tomoiku</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamano</LastName><ForeName>Yasuharu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ando</LastName><ForeName>Miki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Hematology, Juntendo University Graduate School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Immunol</MedlineTA><NlmUniqueID>101560960</NlmUniqueID><ISSNLinking>1664-3224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>PX665RAA3H</RegistryNumber><NameOfSubstance UI="C000722354">ensitrelvir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007191">Indazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014230">Triazoles</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="Y">Hematologic Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016403" MajorTopicYN="Y">Lymphoma, Large B-Cell, Diffuse</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007191" MajorTopicYN="Y">Indazoles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="Y">Triazines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014230" MajorTopicYN="Y">Triazoles</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bruton kinase (BTK) inhibitors</Keyword><Keyword MajorTopicYN="N">COVID-19 PCR cycle threshold (Ct)</Keyword><Keyword MajorTopicYN="N">Long Covid</Keyword><Keyword MajorTopicYN="N">anti-CD20 therapy</Keyword><Keyword MajorTopicYN="N">hematological malignancies</Keyword><Keyword MajorTopicYN="N">immunocompromised</Keyword><Keyword MajorTopicYN="N">protracted SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>10</Day><Hour>22</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>9</Day><Hour>3</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38333218</ArticleId><ArticleId IdType="pmc">PMC10850233</ArticleId><ArticleId IdType="doi">10.3389/fimmu.2024.1287300</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gur I, Giladi A, Isenberg YN, Neuberger A, Stern A. Covid-19 in patients with hematologic Malignancies: clinical manifestations, persistence, and immune response. Acta Haematol (2022) 145(3):297&#x2013;309. doi:&#xa0;10.1159/000523872</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000523872</ArticleId><ArticleId IdType="pmc">PMC9254311</ArticleId><ArticleId IdType="pubmed">35235928</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Tsukune Y, Watanabe N, Sugimoto K, Uchimura A, Tateyama M, et al. . Persistent Covid-19 pneumonia and failure to develop anti-Sars-Cov-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk (2020) 20(11):774&#x2013;6. doi:&#xa0;10.1016/j.clml.2020.08.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7442568</ArticleId><ArticleId IdType="pubmed">32933879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Shah MK, Hoyos D, Solovyov A, Douglas M, Taur Y, et al. . Prolonged Sars-Cov-2 infection in patients with lymphoid Malignancies. Cancer Discovery (2022) 12(1):62&#x2013;73. doi:&#xa0;10.1158/2159-8290.CD-21-1033</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-21-1033</ArticleId><ArticleId IdType="pmc">PMC8758535</ArticleId><ArticleId IdType="pubmed">34753749</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagelmann N, Passamonti F, Wolschke C, Massoud R, Niederwieser C, Adjalle R, et al. . Antibody Response after Vaccination against Sars-Cov-2 in Adults with Hematological Malignancies: A Systematic Review and Meta-Analysis. Haematologica (2022) 107(8):1840&#x2013;9. doi:&#xa0;10.3324/haematol.2021.280163</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2021.280163</ArticleId><ArticleId IdType="pmc">PMC9335098</ArticleId><ArticleId IdType="pubmed">34911284</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JJ, Dong X, Liu GH, Gao YD. Risk and protective factors for Covid-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol (2023) 64(1):90&#x2013;107. doi:&#xa0;10.1007/s12016-022-08921-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-022-08921-5</ArticleId><ArticleId IdType="pmc">PMC8767775</ArticleId><ArticleId IdType="pubmed">35044620</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin M, Zeng X, Duan Y, Yang Z, Ma Y, Yang H, et al. . Molecular mechanism of ensitrelvir inhibiting Sars-Cov-2 main protease and its variants. Commun Biol (2023) 6(1):694. doi:&#xa0;10.1038/s42003-023-05071-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-05071-y</ArticleId><ArticleId IdType="pmc">PMC10322880</ArticleId><ArticleId IdType="pubmed">37407698</ArticleId></ArticleIdList></Reference><Reference><Citation>Antar AAR, Peluso MJ. Croi 2023: acute and post-acute Covid-19. Top Antivir Med (2023) 31(3):493&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10266867</ArticleId><ArticleId IdType="pubmed">37315513</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukae H, Yotsuyanagi H, Ohmagari N, Doi Y, Sakaguchi H, Sonoyama T, et al. . Efficacy and safety of ensitrelvir in patients with mild-to-moderate Coronavirus disease 2019: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study. Clin Infect Dis (2023) 76(8):1403&#x2013;11. doi:&#xa0;10.1093/cid/ciac933</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac933</ArticleId><ArticleId IdType="pmc">PMC10110269</ArticleId><ArticleId IdType="pubmed">36477182</ArticleId></ArticleIdList></Reference><Reference><Citation>Laracy JC, Kamboj M, Vardhana SA. Long and persistent Covid-19 in patients with hematologic Malignancies: from bench to bedside. Curr Opin Infect Dis (2022) 35(4):271&#x2013;9. doi:&#xa0;10.1097/QCO.0000000000000841</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000841</ArticleId><ArticleId IdType="pmc">PMC9922441</ArticleId><ArticleId IdType="pubmed">35849516</ArticleId></ArticleIdList></Reference><Reference><Citation>Longo BM, Venuti F, Gaviraghi A, Lupia T, Ranzani FA, Pepe A, et al. . Sequential or combination treatments as rescue therapies in immunocompromised patients with persistent Sars-Cov-2 infection in the omicron era: A case series. Antibiotics (Basel) (2023) 12(9):1460. doi:&#xa0;10.3390/antibiotics12091460</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics12091460</ArticleId><ArticleId IdType="pmc">PMC10525462</ArticleId><ArticleId IdType="pubmed">37760757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirotsu Y, Kobayashi H, Kakizaki Y, Saito A, Tsutsui T, Kawaguchi M, et al. . Multidrug-resistant mutations to antiviral and antibody therapy in an immunocompromised patient infected with Sars-Cov-2. Med (2023) 4(11):813&#x2013;24 e4. doi:&#xa0;10.1016/j.medj.2023.08.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2023.08.001</ArticleId><ArticleId IdType="pubmed">37683636</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda H, Mori Y, Chiba A, Bai J, Murayama G, Matsushita Y, et al. . Resolution of one-year persisting Covid-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: A follow-up report and literature review of cases with prolonged infections. Clin Lymphoma Myeloma Leuk (2021) 21(10):e810-6. doi:&#xa0;10.1016/j.clml.2021.07.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clml.2021.07.004</ArticleId><ArticleId IdType="pmc">PMC8286809</ArticleId><ArticleId IdType="pubmed">34393077</ArticleId></ArticleIdList></Reference><Reference><Citation>Dulery R, Lamure S, Delord M, Di Blasi R, Chauchet A, Hueso T, et al. . Prolonged in-Hospital Stay and Higher Mortality after Covid-19 among Patients with Non-Hodgkin Lymphoma Treated with B-Cell Depleting Immunotherapy. Am J Hematology (2021) 96(8):934&#x2013;44. doi:&#xa0;10.1002/ajh.26209</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26209</ArticleId><ArticleId IdType="pmc">PMC8212109</ArticleId><ArticleId IdType="pubmed">33909916</ArticleId></ArticleIdList></Reference><Reference><Citation>Hueso T, Pouderoux C, P&#xe9;r&#xe9; H, Beaumont AL, Raillon LA, Ader F, et al. . Convalescent plasma therapy for B-cell-depleted patients with protracted Covid-19. Blood (2020) 136(20):2290&#x2013;5. doi:&#xa0;10.1182/blood.2020008423</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008423</ArticleId><ArticleId IdType="pmc">PMC7702482</ArticleId><ArticleId IdType="pubmed">32959052</ArticleId></ArticleIdList></Reference><Reference><Citation>Betrains A, Godinas L, Woei AJF, Rosseels W, Van Herck Y, Lorent N, et al. . Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (Sars-Cov-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol (2021) 192(6):1100&#x2013;5. doi:&#xa0;10.1111/bjh.17266</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17266</ArticleId><ArticleId IdType="pubmed">33314018</ArticleId></ArticleIdList></Reference><Reference><Citation>Bez P, D'Ippolito G, Deiana CM, Finco Gambier R, Pica A, Costanzo G, et al. . Struggling with Covid-19 in adult inborn errors of immunity patients: A case series of combination therapy and multiple lines of therapy for selected patients. Life (Basel) (2023) 13(7):1530. doi:&#xa0;10.3390/life13071530</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13071530</ArticleId><ArticleId IdType="pmc">PMC10381188</ArticleId><ArticleId IdType="pubmed">37511905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda D, Fukumoto A, Uesugi Y, Tabata R, Miura D, Narita K, et al. . Clinical and immunological characteristics of prolonged Sars-Cov-2 omicron infection in hematologic disease. Blood Cancer J (2023) 13(1):133. doi:&#xa0;10.1038/s41408-023-00897-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41408-023-00897-5</ArticleId><ArticleId IdType="pmc">PMC10477167</ArticleId><ArticleId IdType="pubmed">37666820</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>